Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Company Deals

MediTrust Mabwell Insurance Ecosystem Partnership

Fineline Cube Feb 5, 2026
Company Deals

Pfizer Launches Migraine Management Zone at China Pharmacy

Fineline Cube Feb 5, 2026
Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Fineline Cube Feb 5, 2026
Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026
Hospital Policy / Regulatory

Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care

Fineline Cube Feb 5, 2026
Company Drug

Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors

Fineline Cube Feb 5, 2026
Company Drug

Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors

Fineline Cube Feb 5, 2026
Company Deals

Biosion Secures Series B+ Financing to Advance Antibody-Based Therapies Pipeline

Fineline Cube Apr 23, 2023

Biosion, a global, clinical-stage biotech company dedicated to developing antibody-based therapies for immune and oncologic...

Company

Jiangsu Hengrui Pharmaceuticals Reports 2022 Revenue Dip and Increased R&D Investment

Fineline Cube Apr 23, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a China-based pharmaceutical company, has released its 2022 financial report,...

Company Drug

GenScript Biotech’s Subsidiary Legend Biotech Announces Positive CAR-T Therapy Results

Fineline Cube Apr 23, 2023

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...

Company Deals

HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs

Fineline Cube Apr 21, 2023

China-based HealZen Therapeutics has entered into a licensing agreement with compatriot firm NeuShen, focusing on...

Drug R&D

AACR 2023 Highlights: CAR-T Therapies and Monoclonal Antibody Combinations in Cancer Research

Fineline Cube Apr 21, 2023

The 2023 edition of the American Association for Cancer Research (AACR) annual meeting has concluded,...

Company Deals

Hasten Biopharmaceutical Secures $315 Million Investment for Pipeline Expansion

Fineline Cube Apr 21, 2023

China-based Hasten Biopharmaceutical Co., Ltd has reportedly received USD 315 million in a fundraising round...

Company Deals

Staidson Pharmaceutical Plans RMB 580 Million Private Placement for Drug R&D

Fineline Cube Apr 21, 2023

China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced plans to raise RMB 580...

Company Deals

Sangon Biotech Secures RMB 2 Billion in First Financing Round to Boost Life Science Services

Fineline Cube Apr 21, 2023

China-based contract research organization (CRO) Sangon Biotech has secured RMB 2 billion (USD 290.3 million)...

Company Deals

Shenzhen 01 Life Science Secures RMB 100 Million in Series B1 Financing for Microecology Platform

Fineline Cube Apr 21, 2023

Shenzhen 01 Life Science and Technology Ltd. Co., Ltd, a company specializing in human big...

Company Drug

Pfizer’s Prevenar 13 Receives Expanded Age Range Approval in China

Fineline Cube Apr 21, 2023

U.S.-based pharmaceutical giant Pfizer (NYSE: PFE) has reported receiving an additional indication approval from the...

Company Drug

BeiGene’s Tislelizumab-Chemo Combo Excels in RATIONALE 305 Trial for Gastric Cancer

Fineline Cube Apr 21, 2023

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced that the...

Company Deals

Zylox-Tonbridge Medical Teams Up with Hicicare Science for Guide Wire Product Sales in China

Fineline Cube Apr 21, 2023

China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced...

Company Deals

Shanghai Ark Biopharmaceutical’s STAR Market IPO Filing Accepted, Aims to Raise $289.6 Million

Fineline Cube Apr 21, 2023

Shanghai Ark Biopharmaceutical Co., Ltd’s Initial Public Offering (IPO) filing to the Shanghai Stock Exchange’s...

Company Drug

Hunan Warrant Pharmaceutical Receives NMPA Approval for Generic Brivudine

Fineline Cube Apr 21, 2023

Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving marketing...

Company Drug

Junshi Biosciences’ Tuoyi Combo Shows Promise in Phase III Neotorch Study for NSCLC

Fineline Cube Apr 21, 2023

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has published the results of the Phase III...

Company Deals

Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine’s HIV Drugs

Fineline Cube Apr 21, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a...

Company Medical Device

Acotec Scientific’s Vericor-14 Microcatheter Receives NMPA Approval for Vascular Surgeries

Fineline Cube Apr 21, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National...

Company Drug

Janssen’s Spravato Approved by NMPA for Adult Depression and Suicidal Ideation Treatment

Fineline Cube Apr 21, 2023

Janssen’s Spravato (esketamine) has been granted approval by the National Medical Products Administration (NMPA) in...

Company Drug

Jiangxi Jemincare Group Secures Clinical Trial Approvals for Four Innovative Drugs

Fineline Cube Apr 21, 2023

Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced receiving clinical trial approvals for four...

Company Drug

CSPC Pharmaceutical Group Gets NMPA Approval for SYS6010 ADC Clinical Trial

Fineline Cube Apr 21, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...

Posts pagination

1 … 488 489 490 … 620

Recent updates

  • Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength
  • Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion
  • Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal
  • GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength
  • MediTrust Mabwell Insurance Ecosystem Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength

Company

Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Company Medical Device

GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.